Gene Therapy for Post-Operative Atrial Fibrillation

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-01

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients. The study will assess safety of the intervention in a population at increased risk for post-operative atrial fibrillation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Cardiac Monitoring of Post-Operative Cancer Patients Experiencing Atrial Fibrillation

NCT01253590

Post-Operative Cancer Patients Experiencing Atrial Fibrillation

TERMINATED

Combined Amiodarone and Electrical Cardioversion for Postoperative Atrial Fibrillation After Cardiac Surgery

NCT01558128

Cardiac Disease

TERMINATED NA

A Retrospective Analysis of the Predictive Potential of Pre-operative

NCT00321282

Coronary Artery Bypass

TERMINATED PHASE2

Association of Genetic Polymorphisms With Atrial Fibrosis and Thrombogenic Substrate in Patients With Non-valvular Atrial Fibrillation

NCT03560219

Atrial Fibrillation Thrombosis Stroke +2 more

UNKNOWN

Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation

NCT03269383

Atrial Fibrillation

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post-operative AF (POAF) is a specific form of AF occurring in the days after cardiothoracic surgery. A unique element of POAF is the limited duration of risk, which peaks 3 days and dissipates 10 days after surgery. We propose gene therapy for POAF. Our hypothesis is that counteracting AF-related electrical remodeling will disrupt the reentrant electrical circuits integral to maintaining AF. We have extensive preclinical data showing safety and efficacy of adenoviral gene transfer using the gene mutation KNCH2-G628S. When delivered to the atria using adenoviruses and a novel gene painting technique, KCNH2-G628S effectively and specifically prolongs atrial action potential and prevents development of AF for the 10-14-day duration of post-operative AF risk. This clinical trial will have 2 components: a brief dose-ranging study and a randomized comparison of 2 doses of AdKCNH2-G628S with control cardiac surgery patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Post-operative Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

participant is masked due to delivery during general anesthesia, outcomes assessors and investigators are fully masked to study group.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dose escalation

initial phase, increasing dose

Group Type EXPERIMENTAL

AdKCNH2-G628S

Intervention Type BIOLOGICAL

adenovirus containing the transgene KCNH2-G628S

low dose

second phase, fixed dose 5x10(11) vp

Group Type EXPERIMENTAL

AdKCNH2-G628S

Intervention Type BIOLOGICAL

adenovirus containing the transgene KCNH2-G628S

high dose

second phase, fixed dose 2x10(12) vp

Group Type EXPERIMENTAL

AdKCNH2-G628S

Intervention Type BIOLOGICAL

adenovirus containing the transgene KCNH2-G628S

control

second phase, blinded, randomized with no intervention delivered but with testing and monitoring.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AdKCNH2-G628S

adenovirus containing the transgene KCNH2-G628S

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Elective valve surgery (alone or with coronary artery bypass grafting surgery) and one of the risk factors listed below, or elective coronary artery bypass grafting surgery with two of the risk factors listed below.
* Risk factors:

* age greater than 70,
* increased left atrial size (\> 4 cm left atrial diameter or LA volume index \> 35 on echocardiogram).
* obesity (body mass index \> 30)
* history of:

* paroxysmal AF
* hypertension
* chronic pulmonary disease
* diabetes mellitus
* clinical heart failure
* rheumatic heart disease

Exclusion:

* persistent or permanent AF
* QTc \> 475 on pre-op ECG or any time in last year (unless due to QT prolonging drug that was stopped \> 5 half-lives before surgery with verification of QT normalization after discontinuing drug)
* QTc prolonging drug use (unless stopped \> 5 half-lives prior to surgery)
* Any antiarrhythmic drug use in last year (inclusive of Vaughan Williams class I and III drugs, not including β-blocker or calcium channel blocker drugs)
* Any history of inherited arrhythmia syndrome
* Any prior or current sustained ventricular arrhythmias
* Any prior or current clinically significant bradyarrhythmias unless already treated with pacemaker and ventricular pacing \<20% (to reliable measure QT interval during the study)
* Any prior gene therapy
* Left ventricular ejection fraction (LVEF) \< 35%
* Prior open chest surgery
* History of or current malignancy, unless documented to be cured
* History of or current chemotherapy, radiotherapy, or other immunosuppressive therapy within the past 30 days. Corticosteroid treatment may be permitted at the discretion of the Primary Investigator
* History of infection with human immunodeficiency virus (HIV), hepatitis A, B, or C, or tuberculosis
* Immunizations of any kind in the month prior to surgery
* Underlying defect in immune function or history of multiple or severe life-threatening infections
* Significant liver disease (active hepatitis, AST or ALT greater than twice the upper limit of normal, prior or current liver failure with Pugh-Child category A-C disease)
* Significant renal disease (GFR less than 30)
* Current pregnancy
* Childbearing potential unless participant agrees to prevent pregnancy prior to and for at least 3 months after virus delivery 10
* Any condition that limits life to \< 12 months other than the condition to be treated with the planned surgery
* Participation in any other clinical trial within 30 days of surgery
* Incarcerated persons
* Individuals under the age of 18 years
* Unwillingness to undergo the study interventions and follow-up as outlined in the schedule of events
* Ongoing medical or other condition that is deemed by the Principal Investigator to interfere with the conduct or assessments of the study
* Lack of capacity to provide participant's own informed consent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No